Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Receivables (2021 - 2026)

Immunovant filings provide 5 years of Receivables readings, the most recent being $1.6 million for Q4 2025.

  • Quarterly Receivables fell 26.12% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, down 26.12% year-over-year, with the annual reading at $2.1 million for FY2025, 60.95% down from the prior year.
  • Receivables hit $1.6 million in Q4 2025 for Immunovant, down from $2.0 million in the prior quarter.
  • Across five years, Receivables topped out at $13.2 million in Q2 2022 and bottomed at $596000.0 in Q1 2021.
  • Average Receivables over 5 years is $3.2 million, with a median of $1.9 million recorded in 2025.
  • The largest annual shift saw Receivables soared 1951.85% in 2022 before it plummeted 94.28% in 2023.
  • Immunovant's Receivables stood at $596000.0 in 2021, then rose by 18.12% to $704000.0 in 2022, then surged by 46.16% to $1.0 million in 2023, then soared by 116.13% to $2.2 million in 2024, then fell by 26.12% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Receivables are $1.6 million (Q4 2025), $2.0 million (Q3 2025), and $1.9 million (Q2 2025).